A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
The purpose of this study is to learn more about the safety of DCC 2618 (the study drug) and how well it works against cancer in patients who have received prior anticancer treatment. We will also look at how the study drug may affect your body.
Gastrointestinal Stromal Tumors who have Received Prior Treatment with Imatinib
>18 years of age with previously treated GIST. Various tests and exams will also be done to confirm eligibility.
18 - 100
Healthy Volunteers Needed
Duration of Participation
You may receive the study drug for up to 2 years. You will have a safety follow up visit 30 days after your last dose of study drug and will continue to be contacted by the study staff every 3 months by phone or routine visits to collect long-term data related to your health.
Knight Clinical Trials Office
Deciphera Pharmaceuticals, LLC